Showing 6171-6180 of 10214 results for "".
- Study Highlights Skin Cancer Disparities in Hispanic/Latino Patientshttps://practicaldermatology.com/news/study-highlights-skin-cancer-disparities-in-hispaniclatino-patients/2460950/When Hispanic/Latino people are diagnosed with skin cancer, their tumors are 17 percent larger than tumors in non-Hispanic White patients, a new study shows. For the study, researchers analyzed a total of 3,486 Mohs micrographic surgeries of basal cell, squamous cell, and bas
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Proscia's AI Technology Accurately Identifies Melanomas in Prospective Studyhttps://practicaldermatology.com/news/proscias-ai-technology-accurately-identifies-melanomas-in-prospective-study/2460944/Results of a prospective study just released demonstrate that an artificial intelligence (AI) technology solution from Proscia can automatically detect melanoma with a high degree of accuracy. Conducted at T
- Amgen/Kyowa Kirin's Anti-OX40 Shows Efficacy in Phase 2 for ADhttps://practicaldermatology.com/news/amgenkyowa-kirins-anti-ox40-shows-efficacy-in-phase-2-for-ad/2460943/Positive data from a Phase 2 study of AMG 451/KHK4083, presented at the European Academy of Dermatology and Venereology 30th Virtual Congress, show that the potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic d
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented
- Investigational Agents Show Benefit in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/investigational-agents-show-benefit-in-chronic-spontaneous-urticaria/2460938/Complete control of chronic spontaneous urticaria (CSU) is associated with improvements in key HRQoL measures, such as overall quality of life, sleep interference, activity interference and work impairment, while a marked decline in these improvements to quality of life is seen among patients wit
- New Data Show Itch Reduction with Topical Roflumilast in Psoriasis and Seborrheic Dermatitishttps://practicaldermatology.com/news/new-data-show-itch-reduction-with-topical-roflumilast-in-psoriasis-and-seborrheic-dermatitis/2460937/New patient-reported outcomes data show once-daily, topical roflumilast provides significant reductions in itch. Once-daily roflumilast cream reduced both the severity and burden of itch, and improved quality of life in the DERMIS-1 and DERMIS-2 Phase 3 pivotal studies in chronic plaque psoriasis
- New Data for Galderma’s Nemolizumab Show Rapid Onset in Prurigo Nodularis and Atopic Dermatitishttps://practicaldermatology.com/news/new-data-for-galdermas-nemolizumab-show-rapid-onset-in-prurigo-nodularis-and-atopic-dermatitis/2460935/Investigational monoclonal antibody nemolizumab demonstrates rapid onset of action and significant reduction in symptoms for patients with prurigo nodularis (PN) and atopic dermatitis (AD), according to data presented at the virtual 30th EADV congress and reported by
- No Concerning Safety Signals for Timber's Topical Isotretinoin in Congenital Ichthyosishttps://practicaldermatology.com/news/no-concerning-safety-signals-for-timbers-topical-isotretinoin-in-congenital-ichthyosis/2460934/Phase 2a study results demonstrate no concerning safety signals and no evidence of significant systemic exposure to isotretinoin or tretinoin after 12 weeks of treatment with Timber Pharmaceuticals’ topical isotretinoin formulation (TMB-001) in pa